Critical limb ischemia, always try to revascularize

Original title: Endovascular Treatment for Infrainguinal Vessels in Patients With Critical Limb Ischemia : OLIVE Registry, a Prospective, Multicenter Study in Japan With 12-Month Follow-up. Reference: Osamu Iida et al. Circ Cardiovasc Interv. 2013;6:00-00

Patients with critical limb ischemia typically reveal rest pain and ischemic ulcers or gangrene. Prognosis is poor and mortality and amputation rate are elevated. Bypass surgery has been the gold standard to revascularize those patients, however in real life, critical ischemia is associated with multiple comorbidities that increase the surgical risk.

OLIVE Registry is a prospective multicenter year follow-up study that evaluated the results of percutaneous revascularization in critical ischemia patients and infrainguinal lesions. 314 patients presenting critical isquemia were included, 71% were diabetic, 52% had renal failure and required dialysis and 88% revealed ulcers with tissue loss. 41% of them had lesions below knee and the remaining 42%, femoropopliteal lesions with at least one permeable vessel along the foot. After revascularization at least one direct flow line to the foot was achieved resulting in 93%.

Amputation-free survival was 81% at 6 months and 74% at 12 months. The average time between revascularization and complete healing of the wounds was 97 days. 34% required reoperation at follow up (2.6% and 31.7% new angioplasty).

Conclusion: 

Despite a high rate of reoperations especially for lesions below the knee, percutaneous revascularization was useful in patients with critical ischemia of limb and infrainguinal lesions.

Editorial comment: 

The relatively short period of time (20 months) of those patients included, made the materials used homogeneous throughout the registry and reflect the latest advances in endovascular therapy. This study shows the real life of patients with this disease where several and severe comorbidities are present, making it difficult to think of surgery as the gold standard of treatment.

SOLACI.ORG

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....